Phaseline

Companies › C4 Therapeutics

C4 Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Cemsidomide–Phase 2Multiple Myeloma; Multiple Myeloma (MM)Dec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04756726CemsidomidePhase 1Multiple MyelomaOncologyDec 2026
NCT07280013CemsidomidePhase 1Multiple Myeloma (MM)OncologyDec 2028
NCT07284758CemsidomidePhase 2Multiple MyelomaOncologyMar 2030

From the company's SEC filings

Cash and short-term investments of $275m on 2026-09-30; operating cash outflow about $77m a year; runway about 43 months at that burn, to Apr 2030; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Faeth Therapeutics Puma Biotechnology Black Diamond Therapeutics Kyntra Bio Shanghai Guangsheng Biopharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.